Skip to main content

Advertisement

Table 1 Baseline characteristics of patients (intention to treat population)

From: Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

Parameter Chemotherapy-gefitinib (PCG) (N = 44) (%) Chemotherapy (PC) (N = 46) (%) Total (N = 90) (%) P-value
Age (years)
 Median (range) 60.0 (44–72) 59.0 (37–70) 59.5 (37–72) 0.678
Gender
 Male 35 (79.5) 42 (91.3) 77 (85.6)  
 Female 9 (20.5) 4 (8.7) 13 (14.4) 0.113
Smoking status
 Smoker 37 (84.1) 44 (95.7) 81 (90.0)  
 Non-smoker 7 (15.9) 2 (4.3) 9 (10.0) 0.087
ECOG status
 ECOG 0 0 0 0  
 ECOG 1 44 (100) 46 (100) 90 (100)
Histological subtype
 Adenocarcinoma 24 (54.5) 31 (67.4) 55 (61.1)  
 Non-adenocarcinoma 20 (45.5) 15 (32.6) 35 (38.9) 0.211
EGFR mutation
 Wild-type 6 (13.6) 3 (6.5) 9 (10.0)  
 Unknown 38 (86.4) 43 (93.5) 81 (90.0) 0.157
Stage of disease
 Stage IIIB 8 (18.2) 10 (21.7) 18 (20.0)  
 Stage IV 36 (81.8) 36 (78.3) 72 (80.0) 0.673